A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Cabotegravir Ultra Long-acting (CAB ULA) Following Switch From Cabotegravir Long-acting (CAB LA) in Healthy Adults

Inclusion Criteria:

• Adult participants greater than or equal to (>=) 18 years old, weighing at least 35kg.

• Participants who are overtly healthy as determined by medical evaluation.

• Assigned male sex at birth or assigned female sex at birth. Participants assignedfemale sex at birth are eligible to participate if they are of non-childbearingpotential, or if they are of childbearing potential and are not pregnant (confirmedby test), not breastfeeding, and are using a highly effective contraceptive method.

• Capable of giving written informed consent.

Healthcare staff will be eligible for inclusion in this study if:

• They are site employees responsible for administrative or clinical aspects ofoffering and administering CAB under the protocol at the site.

• Has the required qualifications according to their role and delegated theappropriate responsibilities by site Principal investigator (PI).

• Be able to understand and comply with protocol requirements, instructions, andrestrictions.

Exclusion Criteria:

• Presence or history of cardiovascular, respiratory, hepatic, renal,gastrointestinal, endocrine, haematological, neurological, or psychiatric disorderscapable of significantly altering drug pharmacokinetics, interfering with theparticipant's ability to comply with the dosing schedule and/or protocolevaluations, or compromising participant safety.

• Current or anticipated need for chronic anti-coagulants.

• Any malignancy within the past 5 years except for basal cell or squamous epithelialcarcinomas of the skin that have been resected with no evidence of metastaticdisease for 3 years.

• History of ongoing or clinically relevant seizure disorder within the previous 2years.

• Participants who pose a significant suicidality risk.

• History or presence of sensitivity to any of the study medications, studyprocedure-related medications, their components or drugs of their class, or anallergy that contraindicates participation.

• Participant has an implant/enhancement (including fillers) at the area of proposedinjection; or tattoo or other dermatological condition overlying any area which maysignificantly interfere with interpretation of injection site reactions.

• Inflammatory skin conditions that compromise the safety of injections.

• Any acute laboratory abnormality that should preclude participation or exclusionarylaboratory value.

• Human immunodeficiency virus (HIV-1 or HIV-2) infection.

• Reactive or positive HIV test.

• Signs and symptoms suggestive of acute HIV infection- that is not ruled out withnon-reactive results using appropriate HIV tests.

• Presence of hepatitis B surface antigen (HBsAg) at screening or within 3 monthsprior to first dose of study intervention.

• Positive hepatitis C antibody test result at screening or within 3 months prior tofirst dose of study intervention.

• Positive hepatitis C RNA test result at screening or within 3 months prior to firstdose of study intervention.

• One or more exclusionary values for a screening ECG.

• Participants receiving any protocol-prohibited medication.

• Use of CAB LA for PrEP within 1 year.

• Concurrent participation in another clinical study in which an investigationalproduct was received within 30 days, 5 half-lives or twice the duration of thebiological effect of the investigational product (whichever is longer).

• Participation in the study would result in loss of blood or blood products in excessof 500 mL within 56 days.

• Exposure to more than 4 new chemical entities within 12 months prior to the firstdosing day.

• Positive pre-study drug/alcohol screen.

• History of or on-going high-risk behaviours that put the participant at increasedrisk for HIV infection.